Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC). This is an ASCO Meeting ...

“These students are extraordinary individuals and they don’t hate America,” he said. “Why don’t we vet them first, check their backgrounds, clear them, and tell them, ‘You graduate Harvard, you’re an ...